CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Tollys Makes Philippe Goupit as Chairman of the Board

Life Sciences Review | Wednesday, February 17, 2021
Tweet

This appointment comes at a crucial time for Tollys, with the successful preparation of the next fundraising campaign to finance the first phase I clinical trials, which are scheduled to launch in 2022.


FREMONT, CA: Tollys, a biopharmaceutical firm developing TL-532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, recently announced the appointment of Philippe Goupit as Chairman of the Board of Directors. This appointment comes at a crucial time for Tollys, with the successful preparation of the next fundraising campaign to finance the first phase I clinical trials, which are scheduled to launch in 2022.


“We are thrilled to appoint Philippe Goupit as chairman of the board. His valuable experience and skills will support our ambitions and help strengthen our board of directors at a key stage,” said Jacques-Fran§ois Martin, co-founder and former chairman of the board.


Tollys identified and patented a family of TLR3 agonists and picked TL-532 as its lead candidate. TL-532 is a structurally specified double-stranded, synthetically formed, and highly specific to the TLR3 receptor.


The TLR3 receptor’s specificity and its established 70 base pair sequence separate TL-532 from all other TLR3 agonists studied in clinical trials to date.


“I am honored and very excited to take up this position at Tollys at this specific stage in the development of the company. Thanks to the critical milestones already achieved by the co-founders in establishing the preclinical proof-of-concept of TL-532, it has the potential to become a breakthrough therapy in immuno-oncology,” said Philippe Goupit. “The team, led by Vincent Charlon, Tollys CEO, is excellent and fully capable of meeting the coming challenges within the company.”


In his 35-year career, Philippe worked with various pharmaceutical firms, most recently Sanofi, where he spent more than 20 years; in corporate affairs, deal-making, and strategic positions at the highest global level.  Jacques-Francois Martin, co-founder and former chairman of the board of directors, will remain on the board of directors.


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/tollys-makes-philippe-goupit-as-chairman-of-the-board-nwid-257.html